Protalix BioTherapeutics, Inc.
Assets & Liabilities
| Period | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| Mar 2022 | $75.9M | $68.4M | $16.9M |
| Jun 2022 | $70.5M | $60.6M | $12.5M |
| Sep 2022 | $68.2M | $56.7M | $10.7M |
| Dec 2022 | $66.4M | $55.8M | $17.1M |
| Mar 2023 | $65.6M | $66.6M | $33.0M |
| Jun 2023 | $49.4M | $88.4M | $48.2M |
| Sep 2023 | $49.3M | $87.6M | $20.4M |
| Dec 2023 | $50.9M | $84.4M | $23.6M |
| Mar 2024 | $60.0M | $89.8M | $27.2M |
| Jun 2024 | $63.0M | $91.5M | $23.4M |
| Sep 2024 | $29.1M | $61.6M | $27.4M |
| Dec 2024 | $30.2M | $73.4M | $19.8M |
| Mar 2025 | $28.7M | $73.9M | $19.5M |
| Jun 2025 | $28.6M | $78.5M | $17.9M |
| Sep 2025 | $29.4M | $82.3M | $13.6M |
| Dec 2025 | $34.1M | $82.3M | $14.7M |
| Mar 2026 | $35.1M | $102.3M | $41.0M |
| Jun 2026 | $38.9M | $110.3M | $27.4M |